Enfortumab vedotin for cisplatin-ineligible urothelial cancer Comment

被引：1
|
作者：
Pignot, Geraldine [1 ]
机构：
[1] Inst Paoli Calmettes, Dept Surg Oncol 2, F-13009 Marseille, France
来源：
LANCET ONCOLOGY | 2021年 / 22卷 / 06期
关键词：
D O I：
10.1016/S1470-2045(21)00142-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：748 / 749
页数：2
相关论文
共 50 条
  • [41] KEYNOTE-905/EV-303: A phase 3 study of perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin and cystectomy versus cystectomy alone in cisplatin-ineligible patients with muscle-invasive bladder cancer
    Hennika, Tammy
    Galsky, Matthew D.
    Necchi, Andrea
    Shore, Neal D.
    Plimack, Elizabeth
    Jia, Calvin
    Moreno, Blanca Homet
    Witjes, J. Alfred
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 207 - 208
  • [42] Cabozantinib plus pembrolizumab as first-line therapy for cisplatin-ineligible advanced urothelial carcinoma (PemCab).
    Jain, Rohit K.
    Swami, Umang
    Bilen, Mehmet Asim
    Boucher, Kenneth M.
    Brown, Jacqueline T.
    Chahoud, Jad
    Gupta, Sumati
    Agarwal, Neeraj
    Sonpavde, Guru P.
    Maughan, Benjamin L.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 539 - 539
  • [43] First-line pembrolizumab therapy in a cisplatin-ineligible patient with plasmacytoid urothelial carcinoma: A case report
    Hunter, Lindsay
    Moser, Justin
    Sturge, Caleb
    Barraza, Gonzalo
    Colonna, Sarah
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (01) : 216 - 219
  • [44] Feasibility and efficacy of split-dose cisplatin with atezolizumab for cisplatin-ineligible urothelial carcinoma (SOGUG-AUREA): Final results
    De Velasco Oria, G. A.
    Garcia-Carbonero, I.
    Esteban-Gonzalez, E.
    Pinto, A.
    Lorente, D.
    de Liano Lista, A. Gomez
    Martinez Ortega, E.
    Jimenez Colomo, L.
    Puente, J.
    Gonzalez, I.
    Fernandez Calvo, O.
    Anguera, G.
    ANNALS OF ONCOLOGY, 2024, 35 : S1147 - S1148
  • [45] FDA OKs Enfortumab Vedotin Plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer
    不详
    AMERICAN JOURNAL OF MANAGED CARE, 2024, 30 (02):
  • [46] Enfortumab vedotin and pembrolizumab: redefining the standard of care for previously untreated advanced urothelial cancer
    Sternschuss, Michal
    Rosenberg, Jonathan E.
    FUTURE ONCOLOGY, 2025,
  • [47] Bi -institutional Safety Analysis of Combining Radiotherapy and Enfortumab Vedotin in Advanced Urothelial Cancer
    Soni, Y. S.
    Lock, D.
    Ballas, L. K.
    Hwang, L.
    Cole, S.
    D'Souza, A.
    Zhang, T.
    Garant, A.
    Yang, D. X.
    Arafat, W.
    Desai, N. B.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : S74 - S75
  • [48] Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date
    Moussa, Mohamad
    Papatsoris, Athanasios
    Abou Chakra, Mohamed
    Dellis, Athanasios
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2021, 15 : 453 - 462
  • [49] Neoadjuvant nivolumab (N) plus ipilimumab (I) in cisplatin-ineligible patients with upper tract urothelial cancer (UTUC): Updated results.
    Sternschuss, Michal
    Guercio, Brendan John
    Pietzak, Eugene J.
    Ponomarev, Maria
    Regazzi, Ashley M.
    Quinlan, Colleen
    Aggen, David H.
    Goh, Alvin C.
    Cha, Eugene K.
    Donat, S. Machele
    Hakimi, A. Ari
    Matulewicz, Richard
    Funt, Samuel A.
    Bajorin, Dean F.
    Iyer, Gopa
    Ostrovnaya, Irina
    Al-Ahmadie, Hikmat A.
    Rosenberg, Jonathan E.
    Coleman, Jonathan
    Teo, Min Yuen
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 645 - 645
  • [50] Enfortumab vedotin and pembrolizumab as new first-line standard for metastatic urothelial cancer
    Zhu, Xiaolin
    Koshkin, Vadim S.
    MED, 2024, 5 (02): : 106 - 108
12345